# The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers

> **NCT05152017** · PHASE1 · COMPLETED · sponsor: **St. Petersburg Research Institute of Vaccines and Sera** · enrollment: 75 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Flu-M Quadro [inactivated split influenza vaccine] with preservative
- **BIOLOGICAL:** Flu-M Quadro [inactivated split influenza vaccine] without preservative
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05152017
- **Lead sponsor:** St. Petersburg Research Institute of Vaccines and Sera
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-16
- **Primary completion:** 2020-01-22
- **Final completion:** 2020-01-24
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2022-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05152017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05152017, "The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05152017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*